Pseudomonas aeruginosa Infection in Cancer Patients (Q36756527)

16 August 2017

1 reference

title

Pseudomonas aeruginosa infection in cancer patients (English)

1 reference

16 August 2017

Pseudomonas aeruginosa Infection in Cancer Patients (English)

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

11 November 2022

main subject

Pseudomonas aeruginosa

1 reference

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

11 November 2022

author name string

K. V. Rolston

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735012

11 November 2022

G. P. Bodey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735012

11 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1735012

11 November 2022

publication date

1 January 1992

1 reference

full work available at URL

16 August 2017

http://www.tandfonline.com/doi/pdf/10.3109/07357909209032787

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

11 November 2022

1 reference

16 August 2017

10

1 reference

16 August 2017

1

1 reference

16 August 2017

43-59

1 reference

NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,

16 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Pseudomonas exotoxin shock. A preliminary report of studies in dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Characteristics of nonbacteremic Pseudomonas pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Composition of Pseudomonas aeruginosa slime

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

The slime of Pseudomonas aeruginosa: biological characterization and possible role in experimental infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Gangrenous cellulitis associated with gram-negative bacilli in pancytopenic patients: dilemma with respect to effective therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Necrotizing external otitis in children: report of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Rectal abscesses in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Perirectal infections in acute leukemia. Improved survival after incision and debridement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Pseudomonas aeruginosa bacteremia in patients with neoplastic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Factors Affecting Mortality of Gram-Negative Rod Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

The activity of ceftazidime, other beta-lactams, and aminoglycosides against Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Activity of cefsulodin, other beta-lactams, and aminoglycosides against Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

In vitro activity of BRL 36650, a new semisynthetic penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Infections in cancer patients.Results with gentamicin sulfate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

In vitro activity and disk susceptibility of Timentin: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Carbenicillin Therapy for Pseudomonas Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Fever and infection in leukemic patients.A study of 494 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Ticarcillin plus clavulanic acid in the treatment of patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Beta-lactam regimens for the febrile neutropenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Imipenem-cilastatin as initial therapy for febrile cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

The comparative in-vitro activity of pefloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Intravenous ciprofloxacin for infections in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Survey of antibiotic susceptibility among gram-negative bacilli at a cancer hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Quinolone resistance. Susceptibility data from a 300-bed community hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Antimicrobial Synergism in the Therapy of Gram-Negative Rod Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Prospective study of infections in indwelling central venous catheters using quantitative blood cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Pseudomonas aeruginosa vaccine in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032787

Pseudomonas aeruginosa : Growth in Distilled Water from Hospitals

21 January 2018

2

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Epidemiological Studies of Pseudomonas Species in Patients with Leukemia

11 November 2022

5

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Pseudomonas bacteremia in patients with malignant diseases

11 November 2022

6

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Pseudomonas aeruginosa exotoxin A

11 November 2022

8

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Human Immunity to Pseudomonas aeruginosa. I. In-Vitro Interaction of Bacteria, Polymorphonuclear Leukocytes, and Serum Factors

11 November 2022

22

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Pulmonary host defenses in rabbits after immunization with Pseudomonas antigens: the interaction of bacteria, antibodies, macrophages, and lymphocytes

11 November 2022

23

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

The relationship between the O-antigenic lipopolysaccharides and serological specificity in strains of Pseudomonas aeruginosa of different O-serotypes

11 November 2022

25

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Journal of Infectious Diseases

11 November 2022

27

130

5119

Bjornson A B

1974

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Serum properdin levels and cancer cell homografts in man

11 November 2022

28

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Hair Clipping: Another Hazard for Granulocytopenic Patients?

11 November 2022

32

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Pseudomonas blepharoconjunctivitis: a complication of combination chemotherapy

11 November 2022

33

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Typhlitis: a complication of leukemia in childhood.

11 November 2022

39

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Cytosine arabinoside for localized herpes zoster in patients with cancer: failure in a controlled trial.

11 November 2022

45

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report.

11 November 2022

47

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Pseudomonas aeruginosa Bacteremia: Univariate and Multivariate Analyses of Factors Influencing the Prognosis in 133 Episodes

11 November 2022

49

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Synergy of Carbenicillin and Gentamicin in Experimental Infection with Pseudomonas

11 November 2022

50

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin

11 November 2022

51

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia

11 November 2022

52

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa

11 November 2022

54

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Piroxicam treatment protects mice from lethal pulmonary challenge with Pseudomonas aeruginosa

11 November 2022

57

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Journal of Infectious Diseases

11 November 2022

62

124

5185

Jackson G G

1974

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Clinical and microbiologic consequences of amikacin use during a 42-month period

11 November 2022

65

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

11 November 2022

68

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

11 November 2022

72

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Aztreonam therapy in neutropenic patients with cancer

11 November 2022

78

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Imipenem/cilastatin as secondary therapy for infections in cancer patients

11 November 2022

80

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients

11 November 2022

81

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients

11 November 2022

84

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Oral ciprofloxacin therapy for infections in cancer patients

11 November 2022

89

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Significance of antimicrobial synergism for the outcome of gram negative sepsis

11 November 2022

93

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

11 November 2022

Cancer Treatment Reports

102

67

109

Young L S

1983

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia

11 November 2022

104

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide

11 November 2022

106

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

Considerations for the prevention of infectious complications in patients with cancer.

11 November 2022

109

1 reference

https://api.crossref.org/works/10.3109/07357909209032787

11 November 2022

Identifiers

1 reference

16 August 2017

1 reference